vildagliptin + metformin

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Novartis, Al-Azhar University

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes

Phase 3

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes

CompletedNCT00382096

Novartis PharmaceuticalsDiabetes Mellitus, Type 2

Start: 2006-09-30End: 2008-06-03Updated: 2020-12-19

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

CompletedNCT00468039

NovartisDiabetes Mellitus, Type 2

Start: 2007-03-06End: 2008-06-06Updated: 2020-12-19

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

CompletedNCT00728351

Novartis PharmaceuticalsDiabetes Mellitus, Type 2

Start: 2008-06-30Updated: 2020-12-19

Phase 4

Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors

CompletedNCT07077525

Al-Azhar UniversityType 2 Diabetes

Start: 2023-06-01End: 2024-08-31Updated: 2025-07-22

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01